SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma completed the sale of its Rare Pediatric Disease…

Ascendis Pharma A/S · 6-K filed Jun 17, 2026 at 16:48 ET

At the news

BULLISHIMPACT 7/10

6-K filed Jun 17, 2026 at 16:48 ET

Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash to an undisclosed buyer. The PRV was awarded by the FDA upon approval of YUVIWEL (navepegritide) in February 2026. This non-dilutive cash infusion provides a significant capital boost for the company's operations.

  • Sale of Rare Pediatric Disease Priority Review Voucher (PRV) completed on June 17, 2026
  • Proceeds of $187.5 million in cash, before transaction-related expenses
  • PRV was awarded by FDA upon approval of YUVIWEL (navepegritide) in February 2026
  • Buyer is undisclosed

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access